$GILD 2Q15 Call: Non-GAAP R&D expenses were $702MM, up 30% YoverY due to continued progression and expansion of clinical studies, particularly Phase 3 studies in liver disease and oncology areas. Non-GAAP SG&A expenses were up 34% YoverY to $761MM. Ended 2Q15 with $14.7Bil in cash and investments, and generated cash flow from operations of $5.7Bil.

$VLY priced 8.4MM common shares in a registered public offering. $VLY plans to use proceeds for general corporate purposes, including to supplement the continued growth in the Valley National Bank's loan portfolio. The offering is expected to close on Dec. 13, 2016. Keefe, Bruyette & Woods, A Stifel Company, is acting as sole book-running manager.

$AAL's revenue passenger miles for November 2016 slid 0.2% to 16.8Bil from last year, while available seat miles rose 0.1% to 20.8Bil. Passenger load factor for November 2016 declined 0.3 percentage points to 80.9%. The company now sees 4Q16 total revenue per available seat miles of down 1% to up 1% YoverY and pretax margin excluding items of 6-8%.

$RIG announced the closing of the acquisition of Transocean
Partners. Each outstanding public common unit of Transocean Partners was
converted into the right to receive 1.20 shares of $RIG, which issued approx. 23.8MM
shares related to the transaction. Transocean Partners' common units were
delisted from the NYSE effective December 9, 2016.

$VAC's BoD approved a resolution changing the company's fiscal year
to a calendar year-end beginning with 2017. The company will not restate
historical results as a part of this change. The company's fiscal year 2017
will begin on December 31, 2016 and will end on December 31, 2017.